Aurobindo Pharma has moved higher by 2% at Rs 197 after the company said it has received final approval for Ondansetron Injection, which helps prevent nausea and vomiting caused by cancer chemotherapy and surgery.
“The company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Ondansetron Injection USP 2rng/mL packaged in 40mg/20mL multiple-dose vials and Ondansetron Injection USP 2mg/mL packaged in 4mg/2mL single-dose vials, Preservative-free,” Aurobindo Pharma said in a filing.
Ondansetron Injections are the generic equivalent of GlaxoSmithKline’s Zofran® Injection and indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy or postoperative nausea and/or vomiting, it added.
Aurobindo now has a total of 169 ANDA approvals (143 final approvals including 2 from Aurolife Pharma LLC and 26 tentative approvals) from USFDA.
